TY - JOUR
T1 - The promise of substance P inhibitors in fibromyalgia
AU - Russell, I. Jon
PY - 2002
Y1 - 2002
N2 - The discovery of SP and its potent biological activities have lead to the discovery of other tachykinins and to receptors for them, including the NK1 receptor. Blockade of the NK1 receptor has a number of potentially beneficial effects in medical care including the management of drug-induced emesis and the treatment of depression. The analgesic potential of NK1 receptor antagonists that, in theory, seemed so promising has not met early expectations. However, there is still reason to predict valuable clinical uses for more potent NK1 receptor antagonists in a variety of medical conditions, including FMS.
AB - The discovery of SP and its potent biological activities have lead to the discovery of other tachykinins and to receptors for them, including the NK1 receptor. Blockade of the NK1 receptor has a number of potentially beneficial effects in medical care including the management of drug-induced emesis and the treatment of depression. The analgesic potential of NK1 receptor antagonists that, in theory, seemed so promising has not met early expectations. However, there is still reason to predict valuable clinical uses for more potent NK1 receptor antagonists in a variety of medical conditions, including FMS.
UR - http://www.scopus.com/inward/record.url?scp=0035990361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035990361&partnerID=8YFLogxK
U2 - 10.1016/S0889-857X(01)00006-0
DO - 10.1016/S0889-857X(01)00006-0
M3 - Review article
C2 - 12122921
AN - SCOPUS:0035990361
VL - 28
SP - 329
EP - 342
JO - Rheumatic Disease Clinics of North America
JF - Rheumatic Disease Clinics of North America
SN - 0889-857X
IS - 2
ER -